233 related articles for article (PubMed ID: 21742964)
1. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
Baas JM; Krens LL; Guchelaar HJ; Morreau H; Gelderblom H
Oncologist; 2011; 16(9):1239-49. PubMed ID: 21742964
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
4. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
5. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
7. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
Cejas P; López-Gómez M; Aguayo C; Madero R; Moreno-Rubio J; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Díaz E; Burgos E; Gonzalez-Barón M; Feliu J
Curr Cancer Drug Targets; 2012 Feb; 12(2):124-31. PubMed ID: 22229245
[TBL] [Abstract][Full Text] [Related]
9. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
10. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
11. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
12. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
14. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
[TBL] [Abstract][Full Text] [Related]
15. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
[TBL] [Abstract][Full Text] [Related]
16. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
Kawamoto Y; Tsuchihara K; Yoshino T; Ogasawara N; Kojima M; Takahashi M; Ochiai A; Bando H; Fuse N; Tahara M; Doi T; Esumi H; Komatsu Y; Ohtsu A
Br J Cancer; 2012 Jul; 107(2):340-4. PubMed ID: 22617127
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.
Tímár J; Hegedüs B; Rásó E
Curr Cancer Drug Targets; 2010 Dec; 10(8):813-23. PubMed ID: 20718705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
